QURE Stock Forecast: uniQure NV Price Predictions for 2026-2027

Last close, 20 Nov 2026
$19
−4.35% on the day

The median 12-month analyst price target for uniQure NV is $60. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.4B
Ticker Nerd rank
43/ 100
Median analyst target
$60
Analysts covering
13
Revenue$5.8M+11.0% y/y
Operating income−$44.7M
Net income−$81.1M
Free cash flow−$29.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.7%
1M
−14.8%
YTD
−19.1%
1Y
−30.6%
From 52W high
−62.1%
From 52W low
+114.3%
$9
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores uniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
43/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
88
Growth
79
Value
64
Revisions
56
Accruals
40
Momentum
19
Issuance
17
Volatility
11

Quality (88): The business earns solid, repeatable profits on what it owns.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

QURE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26QUREHigh $93Median $60Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
11
Buy
2
Hold
0
Sell
$27
Low
$60
Median
$93
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
18 Nov 2026HC Wainwright & Co.MaintainsBuy$80 → $65
15 Oct 2026UBSAssumesBuy$27 → $48
5 Oct 2026BarclaysDowngradeEqual-Weight$60 → $28
2 Oct 2026RBC CapitalMaintainsOutperform$65 → $48
30 Sept 2026Goldman SachsMaintainsNeutral$46 → $31
2 Sept 2026William BlairReinstatesOutperform—
30 July 2026BarclaysMaintainsOverweight$65 → $60
30 July 2026Wells FargoMaintainsOverweight$60 → $75
30 July 2026Wolfe ResearchUpgradeOutperform$65
29 June 2026HC Wainwright & Co.MaintainsBuy$50 → $80
25 June 2026MizuhoMaintainsOutperform$35 → $68
18 June 2026BarclaysUpgradeOverweight—
18 June 2026Goldman SachsMaintainsNeutral—
18 June 2026Leerink PartnersMaintainsOutperform—
18 June 2026RBC CapitalMaintainsOutperform—
6 May 2026HC Wainwright & Co.MaintainsBuy—
30 Apr 2026Chardan CapitalMaintainsBuy—
20 Apr 2026Goldman SachsMaintainsNeutral—
23 Mar 2026BarclaysMaintainsEqual-Weight—
11 Mar 2026MizuhoUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QURE.

Market Radar

This page is one stock. Monday covers all of them.

QURE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

QURE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, uniQure NV returned −30.6% against +6.9% for the S&P 500, dividends included.

QURE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26QURES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QURE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
67.3×

Cheaper than 4% of US stocks

Price / book
4.6×

Cheaper than 20% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
94.0%

Higher than 98% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−89.0%

Higher than 15% of US stocks

Return on assets
−13.7%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • uniQure NV has a market value of $1.4B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter grew 11.0% year on year.

  • Net income over the same four quarters: −$252.2M, a −1350.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$161.5M.

  • Shares outstanding: 69.3M.

  • uniQure NV employs 221 people — $84K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

QURE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QUREuniQure NV$1.4B43
INVAInnoviva, Inc.$1.3B74
NUVBNuvation Bio, Inc.$1.3B63
URGNUroGen Pharma Ltd.$1.3B60
ABSIAbsci Corp.$1.3B42
KLRAKailera Therapeutics, Inc.$1.4B3
ADRXADARx Pharmaceuticals, Inc.$1.4B0

Take a look at QURE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own uniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about QURE

What is the QURE stock price forecast for 2026-2027?

The median 12-month analyst price target for uniQure NV is $60, with estimates ranging from $27 to $93. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QURE stock a buy right now?

Of the 13 analysts covering uniQure NV, 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks uniQure NV 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QURE?

As at 21 Nov 2026, uniQure NV ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).

Will QURE stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts is $60, and Ticker Nerd's factor model ranks uniQure NV 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QURE stock forecast for 2030?

No analyst covering uniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $93 over the next 12 months.

How has QURE stock performed over the past year?

uniQure NV returned -30.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does uniQure NV do?

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease.

Company

About uniQure NV.

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.

CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com